Hangzhou Guangdong Hec Technology Holding

Guangdong HEC Technology Holding is a prominent Chinese conglomerate with a significant presence in the pharmaceutical and healthcare sectors through its subsidiaries, most notably YiChang HEC ChangJiang Pharmaceutical. The company is a market leader in anti-influenza medications in China, specifically with its production of Oseltamivir (Kewei). Beyond infectious diseases, HEC has a robust pipeline focusing on metabolic disorders, endocrine diseases, and oncology, with advanced programs in insulin analogues and GLP-1 receptor agonists. The company operates integrated R&D and large-scale manufacturing facilities, positioning itself as a key player in both the domestic Chinese market and international generic and innovative drug spaces.